Comparative Pharmacology
Head-to-head clinical analysis: EMEND versus MECLODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMEND versus MECLODIUM.
EMEND vs MECLODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective substance P/neurokinin 1 (NK1) receptor antagonist, which inhibits the binding of substance P in the emetic pathway.
Meclodium is a synthetic flavonoid derivative with antioxidant and anti-inflammatory properties. It inhibits lipid peroxidation and scavenges free radicals, protecting cell membranes from oxidative damage. It also modulates immune responses by reducing pro-inflammatory cytokine production.
125 mg orally once 1 hour before chemotherapy; then 80 mg orally once daily on Days 2 and 3.
Not a recognized drug.
None Documented
None Documented
9–13 hours (terminal) in healthy adults; clinically, this supports once-daily dosing. In patients with severe renal impairment (CrCl <30 mL/min), half-life is prolonged to ~16 hours.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Primarily metabolized; ~5% unchanged in urine, ~57% in feces as metabolites, ~32% in urine as metabolites. Renal elimination of parent drug is minimal.
Renal: 70% unchanged; Biliary/fecal: 20% as metabolites; 10% minor pathways.
Category C
Category C
Antiemetic
Antiemetic